Neumora Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Neumora Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($56.76M) | Nov 6, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($52.73M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($52.73M) | Aug 6, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($67.99M) | Nov 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($67.99M) | May 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($67.99M) | Aug 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($72.55M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($58.70M) | Aug 6, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($58.70M) | Nov 6, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($53.72M) | Nov 6, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($53.72M) | Aug 6, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($53.72M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($53.03M) | Nov 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($38.54M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($38.54M) | Aug 6, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($35.63M) | Nov 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($35.63M) | May 7, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($35.63M) | Aug 6, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($29.34M) | Nov 1, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($30.37M) | Nov 1, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($57.70M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($54.04M) | Aug 6, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($70.94M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($76.65M) | Nov 6, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($63.82M) | Aug 6, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($60.07M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($56.86M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($42.06M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($39.17M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($30.60M) | Nov 1, 2023 |